Mixed result on Biogen Alzheimer's drug as 6mg dose falls short

July 22 (Reuters) - A 6 mg dose of Biogen's experimental Alzheimer's disease drug significantly reduced beta amyloid plaque in the brain but failed to significantly slow mental decline, potentially tempering great enthusiasm that greeted data on two other doses of the treatment earlier this year.